SerpinB3 upregulates the Cyclooxygenase-2 / β-Catenin positive loop in colorectal cancer
- PMID: 28178650
- PMCID: PMC5362519
- DOI: 10.18632/oncotarget.14997
SerpinB3 upregulates the Cyclooxygenase-2 / β-Catenin positive loop in colorectal cancer
Abstract
Colorectal cancer is characterized by aberrant Cyclooxigenase-2 (COX-2) and β-Catenin pathways. Recently, the protease inhibitor SerpinB3 has been described overexpressed in more advanced stages of this tumor. Aim of the study was to explore the possible relationship between these molecules in this setting. We evaluated colorectal cancer specimens from 105 patients and a positive correlation between SerpinB3, COX-2 and β-Catenin expression was observed, with higher levels in tumor than in adjacent tissue. The highest levels were associated with pathologic parameters of poor prognosis, including vascular invasion, lymph node metastasis and perineural invasion. The molecular and protein profiles of COX-2 and β-Catenin were analyzed in cell lines with different expression of SerpinB3. In those with high expression of SerpinB3, COX-2 and β-Catenin were higher than in controls. Cells with high levels of SerpinB3 showed higher proliferation and invasion compared to controls. In conclusion, in colorectal cancer SerpinB3, COX-2 and β-Catenin are positively correlated and associated with more advanced tumor stage. The in vitro experimental results support a driving role of SerpinB3 in the upregulation of COX-2/ β-Catenin positive loop, associated with a more aggressive cellular phenotype.
Keywords: COX-2; SerpinB3; colorectal cancer; tumor stage; β-Catenin.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis.Br J Cancer. 2014 May 27;110(11):2708-15. doi: 10.1038/bjc.2014.246. Epub 2014 May 8. Br J Cancer. 2014. PMID: 24809782 Free PMC article.
-
Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells.Oncotarget. 2015 Feb 10;6(4):2206-21. doi: 10.18632/oncotarget.2943. Oncotarget. 2015. PMID: 25544768 Free PMC article.
-
Altered distribution of beta-catenin and prognostic roles in colorectal carcinogenesis.Scand J Gastroenterol. 2008;43(4):456-64. doi: 10.1080/00365520701785194. Scand J Gastroenterol. 2008. PMID: 18365911
-
Role of SERPINB3 in hepatocellular carcinoma.Ann Hepatol. 2014 Nov-Dec;13(6):722-7. Ann Hepatol. 2014. PMID: 25332258 Review.
-
Stromal COX-2 signaling are correlated with colorectal cancer: A review.Crit Rev Oncol Hematol. 2016 Nov;107:33-38. doi: 10.1016/j.critrevonc.2016.08.010. Epub 2016 Aug 24. Crit Rev Oncol Hematol. 2016. PMID: 27823649 Review.
Cited by
-
Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma.Cancers (Basel). 2023 Jul 15;15(14):3629. doi: 10.3390/cancers15143629. Cancers (Basel). 2023. PMID: 37509293 Free PMC article. Review.
-
SerpinB3 Upregulates Low-Density Lipoprotein Receptor-Related Protein (LRP) Family Members, Leading to Wnt Signaling Activation and Increased Cell Survival and Invasiveness.Biology (Basel). 2023 May 26;12(6):771. doi: 10.3390/biology12060771. Biology (Basel). 2023. PMID: 37372056 Free PMC article.
-
Low-Dose Acetylsalicylic Acid and Mitochondria-Targeted Antioxidant Mitoquinone Attenuate Non-Alcoholic Steatohepatitis in Mice.Antioxidants (Basel). 2023 Apr 21;12(4):971. doi: 10.3390/antiox12040971. Antioxidants (Basel). 2023. PMID: 37107346 Free PMC article.
-
Epitope-Specific Anti-SerpinB3 Antibodies for SerpinB3 Recognition and Biological Activity Inhibition.Biomolecules. 2023 Apr 25;13(5):739. doi: 10.3390/biom13050739. Biomolecules. 2023. PMID: 37238609 Free PMC article.
-
Upregulation of Serine Proteinase Inhibitor Clade B Member 3 (SERPINB3) Expression by Stromal Cell-Derived Factor (SDF-1)/CXCR4/Nuclear Factor kappa B (NF-κB) Promotes Migration and Invasion of Gastric Cancer Cells.Med Sci Monit. 2020 Oct 28;26:e927411. doi: 10.12659/MSM.927411. Med Sci Monit. 2020. Retraction in: Med Sci Monit. 2023 Jul 28;29:e941964. doi: 10.12659/MSM.941964 PMID: 33110054 Free PMC article. Retracted.
References
-
- Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;29:418–22. - PubMed
-
- Pretlow TP, Pretlow TG. Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer? Biochim Biophys Acta. 2005;1756:83–96. - PubMed
-
- Inoue Y, Saigusa S, Iwata T, Okugawa Y, Toiyama Y, Tanaka K, Uchida K, Mohri Y, Kusunoki M. The prognostic value of KRAS mutations in patients with colorectal cancer. Oncol Reports. 2012;28:1579–84. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
